Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2020

View Archived Issues

Equine encephalitis' entry elucidated

Initiation of RHB-204 phase III trial as first-line treatment of nontuberculous mycobacteria disease

SPL-7013 demonstrates potent antiviral activity against human RSV

MD Anderson and Obsidian collaborate to advance novel cytoTIL therapy for solid tumors

EicOsis completes phase Ia single-ascending dose trial of EC-5026

Immunity stays strong in longest-term COVID study to date

Slowing cholera down protects survivors of infection

Abbisko Therapeutics patents ROR-gammaT agonists

Beijing Jialin Pharmaceutical discloses new SMARCA2-targeting compounds

AiCuris presents new HBV inhibitors

Genfleet Therapeutics synthesizes KRAS inhibitors

Initial phase I data presented for BMS-986253 plus nivolumab in advanced cancer

Early first-in-human data reported for AMG-404

GSK presents phase II data for linerixibat, a potential oral treatment for primary biliary cirrhosis

RAP-011: a sotatercept analogue active in in vivo models of PAH

First cohort dosed in Molecular Partners' phase I study of COVID-19 candidate MP-0420

Tebentafusp improves OS in phase III trial in metastatic uveal melanoma

Bio-Path studies BP-1002 in refractory or relapsed lymphoma and CLL

FDA issues EUA for Regeneron's casirivimab and imdevimab for mild to moderate COVID-19

Neglected tropical ecosystems: Coral reef denizen's microbiome yields candidate Candida fighters

Phase II dosing begins with brequinar to treat COVID-19

Pooled analysis shows AZD-1222 effective at preventing COVID-19

European Commission approves quadrivalent meningococcal conjugate vaccine MenQuadfi